Опыт проведения андрогенозаместительной терапии у больных с возрастным гипогонадизмом, перенесших радикальную позадилонную простатэктомию

1. Han M., Partin A.W., Zahurak M. et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517—523.

2. Slater S., Oliver R.T. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431—9.

3. McConnell J., Denis L., Akaza H. et al. Prostate cancer. Chapter 9. Androgen therapy in men at risk for prostate disease. 2006. p. 360—2.

4. Kaufman J.M., Graydon R.J. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920—2.

5. Agarwal P.K., Oefelein M.G. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533—6.

6. Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482—92.

7. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006;50:935—9.

8. Пушкарь Д.Ю., Сегал А.С. Андрогенозаместительная терапия и состояние предстательной железы. Фарматека 2006;15:62—5.

9. Tubaro A. Testosterone and prostate cancer. Eur Urol 2007;51:293—5.

10. Rhoden E., Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk of prostate cancer: results of 1 year treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170:2348—51.

11. Hoffman M.A., DeWolf W.C., Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824—7.

12. Massengill J.C., Sun L., Moul J.W. et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670—5.